Northern Voices OnlineMannKind’s Inhaled Insulin Tied to Lung Function Concerns (3)BusinessweekMannKind Corp. (MNKD:US)’s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said. Afrezza, a powdered insulin used through an …Questions Raised About Mannkind Diabetes DeviceThe AlmagestInvestors Struggle With Faith In MannKind Prior To FDA Meeting: StockTwitsTheStreet.comMannkind Shares Dip After FDA Group Raises Afrezza ConcernsFox BusinessNorthern Voices Onlineall 22 news articles …Read Full Story
MannKind's Inhaled Insulin Tied to Lung Function Concerns (3) - Businessweek
Real Estate of Cebu
